Tesofensine

Fat LossTriple monoamine reuptake inhibitor / investigationalEmerging

Tesofensine is a triple monoamine reuptake inhibitor. Tesofensine inhibits presynaptic reuptake of noradrenaline, dopamine and serotonin, raising synaptic concentrations of all three. Appetite suppression in clinical studies is attributed mainly to noradrenergic and dopaminergic signalling in hypothalamic circuits regulating food intake.

Calculate Dose

For research use only.

Key Facts

CAS: 195875-84-4
Molecular Weight (MW): 328.3 g/mol
Half-life: —
FDA status: Investigational New Drug (IND)
Evidence level: Clinical Trial Evidence
Human dose established: Yes
Administration Route: Oral
Frequency: Once daily
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026

Vendor price snapshot

Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide: 21
Listed offers: 28
Price per mg (peptide vials): $153.00/mg

By form

Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.

Peptide vials1 vendor · $153.00/mg
Capsules15 vendors · median $3.83/mg
Tablets6 vendors · median $7.17/mg

Open calculator · Compare vendors

Research summary

Small-molecule triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated for obesity. Not FDA-approved. It is widely sold as a research chemical despite having no approved indication in the United States.

Research evidence

Regulatory review (FDA label)None in reviewed sources
Controlled human trials2 reviewed sources
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studiesNone in reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Tesofensine profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Tesofensine dosage evidence

Tesofensine has no approved dosage in the United States or the European Union. Human dosing comes from trials: the phase 2 TIPO-1 obesity trial compared 0.25, 0.5 and 1.0 mg taken by mouth once daily for 24 weeks alongside a calorie-restricted diet, and a later trial in hypothalamic obesity used 0.5 mg combined with 50 mg metoprolol.

Clinical Trial Evidence

Dosage evidence summary for Tesofensine
Human dosing established	Yes
Studied dose range	0.25–1.0 mg once daily in trials
Route	Oral
Frequency	Once daily
Duration studied	24 weeks in the published obesity trials
Evidence level	Clinical Trial Evidence
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Tesofensine, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
TIPO-1 phase 2 obesity trial (2008)Clinical trial · Phase 2 randomised double-blind placebo-controlled trial (NCT00394667)	Adults with obesity, BMI 30–40, on an energy-restricted diet (n=203)	0.25 mg (n=52), 0.5 mg (n=50) or 1.0 mg (n=49), or placebo	Oral	Once daily	24 weeks	Mean weight loss of 4.5%, 9.2% and 10.6% versus 2.0% on diet and placebo; heart rate rose by 7.4 beats per minute at 0.5 mg	Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008.
Tesofensine combined with metoprolol (Tesomet) — hypothalamic obesity (2022)Clinical trial · Randomised controlled trial of a fixed combination	Adults with hypothalamic obesity	0.5 mg tesofensine with 50 mg metoprolol, or placebo	Oral	Once daily	24 weeks	Body weight change	Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022.

Where sources disagree

The largest published obesity trial is the 24-week phase 2 TIPO-1 study, whose authors said its efficacy and safety findings needed confirmation in phase 3 trials.
Tesofensine raises heart rate, which is why it was later tested combined with the beta-blocker metoprolol. Results from the combination do not describe tesofensine taken alone.
Tesofensine is a small-molecule monoamine reuptake inhibitor, not a peptide. It is listed here because it is discussed alongside research peptides for weight loss.

Tesofensine dosage in published studies and labels →

Sequence & molecular data

Sequence and molecular data for Tesofensine
Molecular formula	C17H23Cl2NO
Molecular weight	328.3 g/mol
CAS number	195875-84-4
PubChem CID	11370864
FDA UNII	BLH9UKX9V1
ChEMBL	CHEMBL3989690
DrugBank	DB06156

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Tesofensine inhibits presynaptic reuptake of noradrenaline, dopamine and serotonin, raising synaptic concentrations of all three. Appetite suppression in clinical studies is attributed mainly to noradrenergic and dopaminergic signalling in hypothalamic circuits regulating food intake. Its monoaminergic activity also underlies the cardiovascular effects — increases in heart rate and blood pressure — reported in trials.

Studies

Research statistics

40 PubMed publications · 38.5% human clinical research · 13 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Tesofensine has been studied under an Investigational New Drug application. It is not approved for marketing.

Regulatory and research status for Tesofensine
FDA status	Investigational New Drug (IND)
Research status	Investigational; clinical development reported
Availability	Research-Only
WADA (sport)	Unknown / Not Listed
Library classification	Clinical Trial

How FDA approval, compounding and research-only status differ

Benefits

—

Tesofensine side effects

No side effects listed yet for this entry.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Tesofensine: frequently asked questions

What is Tesofensine?

How does Tesofensine work?

Is Tesofensine FDA approved?

No. Tesofensine is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.

What peptides are similar to Tesofensine?

Compounds most often compared with Tesofensine include 5-Amino-1MQ, SLU-PP-332, BAM15 and AICAR. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Tesofensine profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Tesofensine research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →